Please wait ...

Register for FREE Today!

Can't attend live?
Register anyway for 7-day free access to the summit!


Plus, you can upgrade for unlimited access to the
recording plus earn up to 10 CPD hours!

Register for more information.

  •  
Email*
Confirm email*
First name*
Last name*
 
By signing up, you'll be included in our mailing list and agree to our Privacy Policy, so that you can be the first to hear about exclusive CPD offers and FREE resources from the best therapists in the world!
 
Live 2-Day Free Summit
Psychotherapy Networker's

Psychedelics in Therapy:
MDMA, Psilocybin, Ketamine, Micro-Dosing & More

27-28 July 2022
£349 Standard Price
Can't attend live? Register anyway for 7-day free access to the summit!
Earn up to 10 CPD Hours and gain unlimited access to the recording with optional package! Register for more information.
What You’ll Learn:

This free summit is uniquely designed to provide the skills and insight so you’ll:

  • Know exactly how to talk to clients about psychedelics and their use for PTSD and other mental health concerns

  • Get the most up-to-date training on each of the most widely used substances including MDMA, Ketamine, Psilocybin, and Ayahuasca

  • Know the best paths to go forward if you want to become more involved in psychedelic-assisted therapies

Psychedelics in Therapy Summit Schedule:
Day One | Wednesday 27 July
3:30 PM - 10:15 PM British Summer Time (BST)

Elizabeth Nielson
Psychedelic Harm Reduction and Integration in Clinical Practice
3:30 PM - 4:35 PM BST
Elizabeth Nielson, PhD | Click here for information about Elizabeth Nielson
What do you do when a client lets you know they’re going to use psychedelics on their own? Is there anything you can do to help reduce harm? And what about micro-dosing, which is gaining popularity? This presentation will provide essential information and guidance on how to have these important conversations – including discussions about microdosing, responding to requests for referrals to non-licensed providers, and working with difficult experiences.

Ingmar Gorman
MDMA-Assisted Therapy in the Treatment of Posttraumatic Stress Disorder
4:50 PM - 5:55 PM BST
Ingmar Gorman, PhD | Click here for information about Ingmar Gorman
Early trial studies show that MDMA has incredible potential to treat PTSD, and can even eliminate the PTSD diagnosis all together! Now, with a second trial study nearing completion, and the possibility of MDMA becoming an available treatment in the near future, this is your opportunity to get a full and up-to-date understanding of MDMA-assisted psychotherapy for your practice.

Seema Desai
New Models for Ketamine-Assisted Psychotherapy
6:10 PM - 7:15 PM BST
Seema Desai, MD | Click here for information about Seema Desai
Ketamine is an FDA approved medication that has been used for anaesthesia and pain relief in adults and children for many years. But it has also been researched and used for the treatment of depression, post-traumatic stress disorder, and other “treatment resistant” mental health disorders – with promising results. Now with Ketamine-Assisted Psychotherapy becoming closer to being available for mental health therapists, this is your opportunity to get the latest insights on this developing healing opportunity.

Jeffrey Guss
An Introduction to Ayahuasca for Mental Health Providers
7:50 PM - 8:55 PM BST
Jeffrey Guss, MD | Click here for information about Jeffrey Guss
Ayahuasca is one of the most popular and least understood of the psychedelic agents. In this talk we’ll cover an introduction to ayahuasca, including biochemical, neuroscientific and historical/cultural aspects of its use. Following this, we’ll cover contemporary research on its effects on mental health and its use for treatment of conditions such as addiction and depression. Lastly, some of the psychodynamic aspects of shamanic and syncretic religions settings will be described.

Gabor Maté
When Psychedelics Hurt: Psychedelic Unpleasant Experiences as a Pathway to Healing
9:10 PM - 10:15 PM BST
Gabor Maté, MD | Click here for information about Gabor Maté
Details coming soon...

Day Two | Friday 29 July
2:30 PM - 9:15 PM British Summer Time (BST)

Matthew Johnson
Evidence-Based Therapy Practices in Psilocybin-Assisted Interventions
2:30 PM - 3:35 PM BST
Matthew Johnson, PhD | Click here for information about Matthew W. Johnson
This workshop will explore modern approaches to psychotherapy using the classic psychedelic compound psilocybin. This includes a variety of disorders including substance use disorders, affective, and anxiety disorders. Methods for assuring safety as well as maximizing efficacy will be covered.

Victor Cabral
Psychedelic-Assisted Psychotherapies: A Policy Perspective
3:50 PM - 4:55 PM BST
Victor Cabral, MSW, LSW | Click here for information about Victor Cabral
In anticipation of FDA approval and medicalization, clinicians everywhere are asking to learn more about Psychedelic-Assisted Psychotherapy. But many questions remain unanswered around the current policy landscape and the changes needed to welcome these medicines into our current healthcare system and in psychotherapy. This presentation will provide you with an overview of the history and current state of psychedelic policy and look ahead to what the future holds for clinicians like you to practice psychedelic-assisted therapy.

Phil Wolfson
Integration after Ketamine-Assisted Psychotherapy
5:10 PM - 6:15 PM BST
Phil Wolfson, MD | Click here for information about Phil Wolfson
Details coming soon…

Monnica T. Williams
Psychedelics & Racial Justice
6:50 PM - 7:55 PM BST
Monnica T. Williams, PhD | Click here for information about Monnica T Williams
Psychedelics have been studied for the treatment of PTSD, depression, end-of-life anxiety, OCD, addictions, and a number of other mental health conditions. However, research studies of psychedelic psychotherapies have largely excluded people of colour, leaving important questions unaddressed for these populations. Dr. Williams will review relevant research, documenting exclusion based on the international literature. She will discuss ethnic minority mental health and how psychedelic therapies may help or hinder healing for people of colour. Also discussed are next steps in ensuring that access to culturally-informed care is prioritized as several psychedelics move into late phase trials and expanded access, including the importance of culturally-informed approaches and training focused on therapy providers of colour.

Richard Schwartz
The Internal Family Systems Approach to Psychedelic Experiences
8:10 PM - 9:15 PM BST
Dick Schwartz, PhD | Click here for information about Richard C. Schwartz
The psyche is a delicate ecosystem and psychedelics are powerful agents that can profoundly affect it. While that effect can be positive, there is also the potential for extreme disruption. That’s where Internal Family Systems (IFS) can help therapists and clients alike maintain steady presence and not overreact to sometimes dramatic shifts. In this talk, IFS founder Dick Schwartz will address probable risks and benefits of incorporating psychedelics in the therapy room.

Live 2-Day Free Summit
Psychotherapy Networker's
Psychedelics in Therapy:
MDMA, Psilocybin, Ketamine, Micro-Dosing & More
27-28 July 2022
£349 Standard Price
Can't attend live? Register anyway for 7-day free access to the summit!
Earn up to 10 CPD Hours and gain unlimited access to the recording with optional package! Register for more information.
Expert Faculty:

Richard Schwartz
Richard Schwartz, PhD, is the founder of Internal Family Systems (IFS) therapy model. He now serves on the Faculty of the Department of Psychiatry at Harvard Medical School and is a Senior Fellow of the Meadows treatment centre in Arizona. In 2000, he founded the Center for Self Leadership (now IFS Institute), which offers three levels of trainings and workshops in IFS for professionals and the general public, both in this country and abroad. A featured speaker for national professional organizations, Dr. Schwartz has published many books and over fifty articles about IFS.

Gabor Maté
Gabor Maté, MD, is a renowned speaker and bestselling author. He is highly sought after for his expertise on a range of topics including trauma treatment, addiction, stress and childhood development. As an author, Dr. Maté has written several bestselling books including the award-winning In the Realm of Hungry Ghosts: Close Encounters with Addiction; When the Body Says No; The Cost of Hidden Stress; and Scattered Minds: A New Look at the Origins and Healing of Attention Deficit Disorder, as well as the newly released The Myth of Normal.

Elizabeth Nielson
Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders.

Ingmar Gorman
Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike.

Seema Desai
Seema Desai, MD, is a board-certified child, adolescent, and adult psychiatrist with a clinical interest in the intersection of spirituality and psychiatry. She is currently a study therapist in a MAPS trial examining the effects of MDMA for the treatment of PTSD. She offers psychopharmacology treatment and ketamine-assisted psychotherapy in her private practice.

Jeffrey Guss
Jeffrey Guss, MD, is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy, addictions and psychedelic therapy. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psilocybin-assisted psychotherapy in the treatment of cancer related existential distress, and is currently is a study therapist on studies of Psilocybin-Assisted treatment of Major Depressive Disorder and MDMA-Assisted Psychotherapy for PTSD.

Matthew Johnson
Matthew Johnson, PhD, is The Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research at Johns Hopkins. Working with psychedelics since 2004, he is one of the world’s most widely published experts on psychedelics. He has published research on psychedelics and mystical experience, personality change, tobacco smoking cessation, cancer distress treatment, and depression treatment. In 2021 he received as principal investigator the first grant in 50 years from the US government for a treatment study with a classic psychedelic, specifically psilocybin in treatment of tobacco addiction. He is also known for his expertise in behavioural economics, addiction, sexual risk behaviour, and research with a wide variety of drug classes.

Victor Cabral
Victor Cabral, MSW, LSW, CCTP-I, is the Founder of Dreamers of the Day LLC. and serves as the Director of Policy and Regulatory Affairs for Fluence International Inc., a company that provides evidence-based training in psychedelic therapy and integration services to clinicians across the globe.

Phil Wolfson
Phil Wolfson, MD, is president and CEO of the non-profit Ketamine Research Foundation and directs the training of KAP practitioners through The Ketamine Training Center. Phil’s book, The Ketamine Papers, is the seminal work in the burgeoning ketamine arena. His is principal investigator for the MAPS sponsored Phase 2, the FDA-approved 18-person study of MDMA-Assisted Psychotherapy for individuals with significant anxiety due to life threatening illnesses. His clinical practice with ketamine has informed his leadership role in the development of Ketamine-Assisted Psychotherapy.

Monnica T. Williams
Monnica T. Williams, PhD, is a board-certified licensed clinical psychologist who was named one of the top 25 thought leaders in PTSD by PTSD Journal. Her work has been featured in several major media outlets, including NPR, Huffington Post, CNN, and the New York Times. Dr. Williams has published over 100 book chapters and peer-reviewed articles focused on trauma and other anxiety-related disorders and cultural differences. She is currently an Associate Professor at the University of Ottawa in the School of Psychology, where she is the Canada Research Chair for Mental Health Disparities. She is also Clinical Director of the Behavioral Wellness Clinic in Connecticut, where she provides supervision and training to clinicians for empirically-supported treatments.


Live 2-Day Free Virtual Training
Psychotherapy Networker's
Psychedelics in Therapy:
MDMA, Psilocybin, Ketamine, Micro-Dosing & More
July 27-28, 2022
$439 Value
Can't attend live? Register anyway for 14-day free access to the training!
Earn up to 10 CE Hours with optional package! Register for more information.
FAQs

No catch. Over the last few years, thanks to the generosity of our expert speakers and the support of therapists like you, we've had the amazing opportunity to provide professional training to more therapists than ever

Because psychedelic-assisted therapy is something all therapists need to know about, we wanted to pull together the very best of the best into an exclusive 2-day training that’s accessible to all therapists. It helps the field and in turn, helps us fulfill our mission.


Yes! Even if you won't go further and practice psychedelic-assisted therapies, we all need to understand this rapidly growing area of therapy. Clients are asking us about it, they are using psychedelics on their own, and many clients will come to your practice having been to ketamine clinics or other psychedelic therapies. Plus, your clients will need help navigating this world of therapies safely, and they need you to help them better understand the risks and benefits as they look to integrate these experiences.

Even if you're not a PAP therapist - you can help! This Summit is designed for you!


Psychotherapy Networker is a non-profit educational organization. For over 46 years our magazine, CE trainings, and annual Symposium have featured the leading researchers, innovators, and developers in the field through our award-winning magazine, CE trainings, and our annual Symposium.

Our focus is on telling the stories of psychotherapy and being a place where clinicians of all licenses and backgrounds who practice psychotherapy can keep up on what's happening in the field, hear captivating stories from colleagues on what's really happening in their practices, learn through CE trainings from the best in the field, and enjoy the most celebrated annual gathering of psychotherapists in the world each year in March in Washington DC!


Yes! We designed it so you'll get at least 1 hour on EVERY major psychedelic agent being used today PLUS workshops on integration (after a psychedelic experience) and harm reduction (when clients use on their own or outside of a licensed clinic) - as well as regulations, risks and benefits, ethics, and more!


No -- psychedelic-assisted therapies are here NOW. Ketamine clinics are all over the US. Psilocybin is used more widely. People are going on Ayahuasca trips, and many clients are obtaining these substances on their own and using them, sometimes without supervision. Right now, licensed mental health professionals can engage in harm reduction practices (for when clients use outside of a licensed clinic) and in integration (helping clients integrated psychedelic experiences) and provide needed accurate information about risks and benefits.

This Summit is designed for exactly that -- practical guidance not just for the future, but right here, right now.


Yes! The full recording package (that includes up to 10 self-study CE hours) is just $59.99, offered ONLY for those who register here until the end of the summit on July 28th. After that the price is set at $439. Just register today above with your name and email, then click the "Self Study" CE button that includes unlimited access to all the recordings, plus self-study CE credits.


Just register today above with your name and email, then click the "LIVE CE" button on the next page to purchase your credit package for just $49.99 (discounted from $439.99) - only available for those who register here and purchase before the end of the Summit on July 28th.


Yes! Just register above and then click the "Self Study" CE button on the next page and purchase the Conference Recordings package. You'll get unlimited access to the summit and be able to earn CE on each session at any time in the future.


YES! All sessions are completely LIVE and you'll be able to engage with the presenters and chat with colleagues throughout each presentation.


Complete program details and speaker bios are above. But once you register with your name and email address, there will be a link to a downloadable PDF of the schedule.


Yes! You get unlimited replay access for 14 days after the Summit. Replays will appear about 2-4 hours after the live session ends and will be in the same place where the live session took place in your Psychotherapy Networker CE account portal.

Live 2-Day Free Summit
Psychotherapy Networker's
Psychedelics in Therapy:
MDMA, Psilocybin, Ketamine, Micro-Dosing & More
27-28 July 2022
£349 Standard Price
Can't attend live? Register anyway for 7-day free access to the summit!
Earn up to 10 CPD Hours and gain unlimited access to the recording with optional package! Register for more information.

NOTE: No additional discounts or coupons may be applied to this course.
SUM001612 • © PESI UK • All rights reserved
Back to Top